Thomas C. Blevins MD
Diabetes, Lipid Metabolism
Endocrinologist, Texas Diabetes & Endocrinology
Join to View Full Profile
6500 N Mopac ExpyBldg 3Austin, TX 78731
Phone+1 512-458-8400
Fax+1 512-458-8593
Dr. Blevins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1984 - 1986- Baylor College of MedicineResidency, Internal Medicine, 1981 - 1984
- Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1981 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Diabetes Recognition Program National Committee for Quality Assurance, 2012-2015
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port Start of enrollment: 2006 Oct 01
- Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port Start of enrollment: 2009 Aug 01
- A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Safety and Efficacy of Inhaled TechnosphereInsulin in the Postprandial Period With Modified Initial Dose Conversion.Christopher Jacobson, Kevin B Kaiserman, Johanna Ulloa, Jennifer Pleitez, Joseph Sylvan
Diabetes Therapy. 2025-08-01 - Methylglyoxal-induced RNA modifications decrease RNA stability and translation and are associated with type 2 diabetes.Edwin De Jesus Lopez Gonzalez, Swt Lai, Kelani Sun, Caree R Carson, Carlos Hernandez-Castillo
Molecular Metabolism. 2025-08-01 - 2 citationsOnce-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, ...Thomas Blevins, Dominik Dahl, Federico C Pérez Manghi, Sreenivasa Murthy, Ramon Ortiz Carrasquillo
Lancet. 2025-06-28
Journal Articles
- Efficacy and Safety of MYL‐1501D Versus Insulin Glargine in Patients with Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 StudyThomas Blevins, MD, Diabetes, Obesity and Metabolism
Press Mentions
QWINT Signals Paradigm Shift for Basal Insulin Dosing in Type 2 DiabetesJune 23rd, 2025- Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 DiabetesJune 22nd, 2025
- Symposium Will Discuss QWINT Results That Could Signal Paradigm Shift in Basal Insulin DosingMay 30th, 2025
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
